RSV604

HY-12993		
676128-63-5		
C ₂₂ H ₁₇ FN ₄ O ₂		
388.39		
RSV		
Anti-infection		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year
	676128-63-3 C ₂₂ H ₁₇ FN ₄ O ₂ 388.39 RSV Anti-infection Powder	676128-63-5 $C_{22}H_{17}FN_4O_2$ 388.39 RSV Anti-infection Powder -20°C 4°C In solvent -80°C

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (257.47 mM; Need ultrasonic)						
	Preparing Stock Solutions	Mass Solvent Concentration	1 mg	5 mg	10 mg		
		1 mM	2.5747 mL	12.8737 mL	25.7473 mL		
		5 mM	0.5149 mL	2.5747 mL	5.1495 mL		
		10 mM	0.2575 mL	1.2874 mL	2.5747 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution						

BIOLOGICAL ACTIVITY				
Description	RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a K _d of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC ₅₀ s=0.8 μM) ^{[1][2]} .			
IC ₅₀ & Target	Kd: 1.6 μM (nucleocapsid protein) ^[2]			
In Vitro	RSV604 (5 days) inhibits the growth of four laboratory strains of RSV (RSS, Long, A2 and B), with EC ₅₀ s ranging from 0.5 to 0.9			

NH

ő

 μ M in plaque reduction assay^[1].

RSV604 (6 days) inhibits RSV-induced HEp-2 cell death, with an EC_{50} of 0.86 μ M^[1].

RSV604 (3 days) reduces viral antigen synthesis in RSV-infected HEp-2 cells, with an EC_{50} of 1.7 μ M^[1].

RSV604 (1-20 µM; 7 days) dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells, with no gross

cytotoxicity, leakage of basolateral fluid to the apical surface, or alteration of cilium beat frequency^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Enzyme Inhib Med Chem. 2022 Dec;37(1):2598-2604.
- J Org Chem. 2020 Mar 20;85(6):4267-4278.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53.

[2]. Challa S, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA